Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.
Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, Kang Y, Su JG, Zhang J, Yang T, Hussein S, ElDein MS, Yang SS, Lei W, Gao XJ, Jiang Z, Cong X, Tan Y, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Hou JW, Lei ZH, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: yang t, yang xm, yang yk, yang ss, yang m. Nat Commun. 2022 Jun 27;13(1):3654. doi: 10.1038/s41467-022-31379-0. Nat Commun. 2022. PMID: 35760812 Free PMC article. Clinical Trial.
Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial.
Kaabi NA, Yang YK, Liang Y, Xu K, Zhang XF, Kang Y, Jin YQ, Hou JW, Zhang J, Yang T, Hussein S, ElDein MS, Lei ZH, Zhang H, Shao S, Liu ZM, Liu N, Zheng X, Su JG, Yang SS, Cong X, Tan Y, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Shen FJ, Wu JJ, Han ZB, Du LF, Tang F, Chen S, Ma ZJ, Zheng F, Hou YN, Li XY, Li X, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: yang t, yang xm, yang yk, yang ss, yang m. Signal Transduct Target Ther. 2023 Jan 3;8(1):20. doi: 10.1038/s41392-022-01295-2. Signal Transduct Target Ther. 2023. PMID: 36596779 Free PMC article. Clinical Trial.
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.
Kaabi NA, Yang YK, Zhang J, Xu K, Liang Y, Kang Y, Su JG, Yang T, Hussein S, ElDein MS, Shao S, Yang SS, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Liu N, Shen FJ, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: yang t, yang xm, yang yk, yang ss, yang m. Signal Transduct Target Ther. 2022 Jun 6;7(1):172. doi: 10.1038/s41392-022-00984-2. Signal Transduct Target Ther. 2022. PMID: 35665745 Free PMC article. Clinical Trial.
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals.
Liu CH, Chang YP, Lee JY, Chen CY, Kao WY, Lin CL, Yang SS, Shih YL, Peng CY, Lee FJ, Tsai MC, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH. Liu CH, et al. Among authors: yang ss. J Med Virol. 2024 May;96(5):e29675. doi: 10.1002/jmv.29675. J Med Virol. 2024. PMID: 38746997
1,429 results